NCT03320330: Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 26 | US | Laboratory Biomarker Analysis, Pepinemab, moAb VX15/2503, VX15/2503, Pharmacological Study | Children's Oncology Group, National Cancer Institute (NCI) | Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma | 12/20 | 09/24 | | |
NCT03205644: VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 75 | US | Anti-SEMA4D Monoclonal Antibody VX15/2503, moAb VX15/2503, VX15/2503, Laboratory Biomarker Analysis, Pharmacological Study | Children's Oncology Group, National Cancer Institute (NCI), COG Phase I Consortium | Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Malignant Solid Neoplasm | 09/21 | 10/21 | | |
